4MOVING BIOTECH
🇫🇷France
Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- 4Moving Biotech
- Target Recruit Count
- 34
- Registration Number
- NCT05419856
- Locations
- 🇧🇪
UCL-St Luc, Brussels, Belgium
🇧🇪AZMaria Middelares, Gent, Belgium
🇧🇪UZ Leuven, Louvain, Belgium
News
4Moving Biotech Initiates Phase 2a Trial of First-in-Class GLP-1 Therapy for Knee Osteoarthritis
4Moving Biotech has enrolled the first patient in INFLAM MOTION, a Phase 2a trial evaluating 4P004, an intra-articular GLP-1 analog for knee osteoarthritis treatment.
Health Canada Authorizes 4Moving Biotech's Phase 2a Trial for Novel Knee Osteoarthritis Treatment
Health Canada has approved 4Moving Biotech's INFLAM MOTION Phase 2a clinical trial for 4P004, a GLP-1 analog designed for intra-articular use in knee osteoarthritis patients.